Quiz|Articles|September 13, 2026 (Updated: September 10, 2026)
NeurologyLive® Brain Games: September 13, 2026
Author(s)Louie Pasculli, Marco Meglio
Listen
0:00 / 0:00
Key Takeaways
- A weekly cadence delivers three-question quizzes designed to test broad neurologic knowledge across both clinical practice and historical context.
- Topics routinely span dementia/Alzheimer disease, epilepsy, headache/migraine, movement disorders, multiple sclerosis, neuromuscular disease, sleep medicine, and cerebrovascular syndromes.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is emerging muscular dystrophy agents!
Advertisement
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions includes the theme of emerging muscular dystrophy agents!
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email:
A patient with Duchenne muscular dystrophy is being evaluated for an investigational therapy designed to increase dystrophin expression through RNA-based exon skipping. Which molecular outcome would most directly demonstrate successful target engagement?
An investigational muscular dystrophy therapy uses a cardiac-derived cell therapy intended to improve skeletal and cardiac muscle function. Which characteristic most distinguishes this therapeutic strategy from conventional small-molecule therapies?
A patient with myotonic dystrophy is being considered for an investigational antisense oligonucleotide designed to target the molecular abnormality responsible for toxic RNA-mediated disease. Which mechanism best describes the therapeutic rationale?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Apitegromab for Spinal Muscular Atrophy
2
AAN, AHS Issue Updated Guideline on Pharmacologic Migraine Prevention in Adults: FAQs
3
AAN, AHS Issue Updated Guideline on Migraine Prevention, Atogepant Meets End Points in Phase 3 Trial, Trientine Enters Phase 3 Trial
4
Exploring the Link Between Football Players and ALS: Rory Siegel, DO
5